<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02177032</url>
  </required_header>
  <id_info>
    <org_study_id>V49_30</org_study_id>
    <secondary_id>2013-CT0191</secondary_id>
    <nct_id>NCT02177032</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity of Two Intradermal Rabies Vaccine Regimens Administered With and Without Human Rabies Immunoglobulin in Subjects ≥ 1 Years of Age</brief_title>
  <official_title>Phase 3, Randomized, Stratified, Open Label, Multicenter, Controlled Clinical Study to Evaluate Safety and Immunogenicity of a Rabies Vaccine Administered, With and Without Human Rabies Immunoglobulin, Using the New &quot;4-sites, 1-week&quot; Intradermal Regimen for Postexposure Prophylaxis Compared to the Currently Recommended &quot;2-sites, TRC&quot; Intradermal Regimen in Children and Adults Subjects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Vaccines</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Demonstrate non-inferiority of the immune response between new versus the currently
      recommended intradermal regimens of rabies vaccine when administered with or without rabies
      immunoglobulins in healthy subjects ≥ 1 years of age.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentages of Subjects With RVNA Titer &gt;= 0.5 and Vaccine Group Differences (&quot;4-sites, 1-week&quot; to That of &quot;2-sites, TRC&quot; ID PEP Regimen of the PCEC Rabies Vaccine With or Without HRIG Administration)</measure>
    <time_frame>Study day 50 (D50)</time_frame>
    <description>Vaccine group differences are calculated assuming a binomial distribution and the associated confidence interval for the differences in percentage was based on M-N method.
Non-inferiority of the immune response of the new &quot;4-sites, 1-week&quot; ID PEP regimen of the PCEC vaccine, with or without HRIG administration, to that of the currently recommended &quot;2-sites, TRC&quot; ID PEP regimen of the PCEC rabies vaccine with or without HRIG administration, as measured by the percentage of subjects with RVNA titer ≥ 0.5 IU/ml at day 50 in the whole study population.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Rabies Virus Neutralizing Antibody (RVNA) Concentration and Between-group (2 ID Rabies Vaccine Regimens (4-sites, 1-week and 2-sites, TRC) With or Without HRIG) Ratio of GMCs</measure>
    <time_frame>Study Day 50</time_frame>
    <description>Immunogenicity was assessed in terms of Geometric Mean Rabies Virus Neutralizing Antibody (RVNA) Concentration in Children and Adult Subjects, ≥ 1 Years of Age at day 50 The GMCs, GMRs (i.e., within group ratio) and associated two sided 95% confidence intervals for each group were computed by exponentiating (base 10) of the least square means of the logarithmically transformed (base 10) concentration (and their differences) and the 95% CIs obtained from an Analysis of variance (ANOVA) with vaccine regimen, age strata and center as factors.
Non-inferiority of the immune response between the 2 ID rabies vaccine regimens (4-sites, 1-week and 2-sites, TRC) with or without HRIG administration as measured by RVNA GMCs at day 50 in the whole study population.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Rabies Virus Neutralizing Antibody Concentration at Days 8, 15, 91, 181 and 366 &amp; Between-group (2 ID Rabies Vaccine Regimens (4-sites,1-week &amp; 2-sites, TRC) With or Without HRIG) Ratio of GMCs in Children &amp; Adult Subjects,≥ 1 Years of Age</measure>
    <time_frame>At Days 8, 15, 91, 181 and 366</time_frame>
    <description>Immunogenicity was assessed in terms of the Geometric Mean Rabies Virus Neutralizing Antibody (RVNA) Concentration at Days 8, 15, 91, 181 and 366 in Children and Adult Subjects, ≥ 1 Years of Age The GMCs, GMRs (i.e., within group ratio) and associated two sided 95% confidence intervals for each group were computed by exponentiating (base 10) of the least square means of the logarithmically transformed (base 10) concentration (and their differences) and the 95% CIs obtained from an Analysis of variance (ANOVA) with vaccine regimen, age strata and center as factors.
Non-inferiority of the immune response between the 2 ID rabies vaccine regimens (4-sites, 1-week and 2-sites, TRC) with or without HRIG administration as measured by RVNA GMCs at day 50 in the whole study population.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects With Anti-RVNA Titer ≥0.5 IU/mL at Days 8, 15, 91, 181 and 366 in Children and Adult Subjects and Vaccine Group Differences (2 ID Rabies Vaccine Regimens (4-sites, 1-week and 2-sites, TRC), With or Without HRIG), ≥ 1 Years of Age</measure>
    <time_frame>At Days 8, 15, 91, 181 and 366</time_frame>
    <description>Vaccine group differences are calculated assuming a binomial distribution and the associated confidence interval for the differences in percentage was based on M-N method.
RVNA percentage of subjects with RVNA titer ≥ 0.5 IU/mL at study days 8, 15, 91, 181, and 366 following administration of the 2 ID rabies vaccine regimens (4-sites, 1-week and 2-sites, TRC), with or without HRIG, in the whole study population.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Rabies Virus Neutralizing Antibody (RVNA) Concentration and Vaccine Group Differences in Adult Subjects, ≥ 18 Years of Age</measure>
    <time_frame>At Days 8, 15, 50, 91, 181 and 366</time_frame>
    <description>Immunogenicity was assessed in terms of the Geometric Mean Rabies Virus Neutralizing Antibody (RVNA) Concentration at Days 8, 15, 50,91, 181 and 366 in Adult Subjects, ≥ 18 Years of Age.
RVNA GMCs with RVNA titer ≥ 0.5 IU/mL at days 8, 15, 50, 91, 181 and 366 and group differences (4-sites,1-week without HRIG versus 4-sites,1-week with HRIG; 4-sites,1-week with HRIG versus 2-sites,TRC with HRIG; 4-sites,1-week without HRIG versus 2-sites, TRC without HRIG)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects With Anti-RVNA Titer ≥0.5 IU/mL in Adult Subjects, ≥ 18 Years of Age</measure>
    <time_frame>At Days 8, 15,50, 91, 181 and 366</time_frame>
    <description>Immunogenicity was assessed in terms of the Percentages of Subjects With Anti-RVNA concentration ≥0.5 IU/mL at Days 8, 15, 50, 91, 181 and 366 in Adult Subjects, ≥ 18 Years of Age.
Percentage of subjects with RVNA titer ≥ 0.5 IU/mL at days 8, 15, 50, 91, 181 and 366 and group differences (4-sites,1-week without HRIG versus 4-sites,1-week with HRIG; 4-sites,1-week with HRIG versus 2-sites,TRC with HRIG; 4-sites,1-week without HRIG versus 2-sites, TRC without HRIG)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Rabies Virus Neutralizing Antibody (RVNA) Concentration in Children and Adult Subjects, ≥ 1 Years of Age</measure>
    <time_frame>At Days 8, 15, 50, 91, 181 and 366</time_frame>
    <description>Immunogenicity was assessed in terms of the Geometric Mean Rabies Virus Neutralizing Antibody (RVNA) Concentration at Days 8, 15, 50, 91, 181 and 366 in Children and Adult Subjects, ≥ 1 Years of Age</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects With Anti-RVNA Titer ≥0.5 IU/mL in Children and Adult Subjects, ≥ 1 Years of Age</measure>
    <time_frame>At Days 8, 15, 50, 91, 181 and 366</time_frame>
    <description>Immunogenicity was assessed in terms of the Percentages of Subjects With Anti-RVNA concentration ≥0.5 IU/mL at Days 8, 15, 50, 91, 181 and 366 in Children and Adult Subjects, ≥ 1 Years of Age</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Who Reported Solicited Local and Systemic Adverse Events After Any Vaccination</measure>
    <time_frame>From day 1 to day 3; from day 4 to day 7; from day 8 to day 14; from day 29 to day 35(2-sites, TRC PEP, ID regimen)</time_frame>
    <description>Number of subjects Who Reported Solicited Local and Systemic Adverse Events After Any Vaccination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Unsolicited Adverse Events (AEs)</measure>
    <time_frame>Day 1 to Day 366</time_frame>
    <description>Safety was assessed in terms of the Number of Subjects Reporting Unsolicited Adverse Events (AEs)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Rabies Virus Neutralizing Antibody (RVNA) Concentration ≥0.5 IU/mL and Vaccine Group Differences in Adult Subjects, ≥ 18 Years of Age</measure>
    <time_frame>At Days 8, 15, 50, 91, 181 and 366</time_frame>
    <description>Immunogenicity was assessed in terms of the Geometric Mean Rabies Virus Neutralizing Antibody (RVNA) Concentration ≥0.5 IU/mL at Days 8, 15, 50,91, 181 and 366 in Adult Subjects, ≥ 18 Years of Age</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects With Anti-RVNA Titer ≥0.5 IU/mL in Adult Subjects, ≥ 18 Years of Age</measure>
    <time_frame>At Days 8, 15,50, 91, 181 and 366</time_frame>
    <description>Immunogenicity was assessed in terms of the number of subjects With Anti-RVNA concentration ≥0.5 IU/mL at Days 8, 15, 50, 91, 181 and 366 in Adult Subjects, ≥ 18 Years of Age</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">885</enrollment>
  <condition>Rabies Infection</condition>
  <arm_group>
    <arm_group_label>4-sites, 1-week without HRIG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PCEC rabies vaccine, administered ID according to the &quot;4-sites, 1-week&quot; regimen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4-sites, 1-week with HRIG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PCEC rabies vaccine, administered ID to adults, according to the &quot;4-sites, 1-week&quot; regimen plus HRIG</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2-sites, TRC without HRIG</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PCEC rabies vaccine, administered ID according to the &quot;2-sites, TRC&quot; regimen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2-sites, TRC with HRIG</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PCEC rabies vaccine, administered ID to adults , according to the &quot;2-sites, TRC&quot; regimen plus HRIG</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Rabies vaccine</intervention_name>
    <description>12 doses of the PCEC rabies vaccine, administered ID (0.1mL for each injection) according to the &quot;4-sites, 1-week&quot; regimen (i.e. 4 doses of vaccine; in both deltoids and anterolateral thigh areas, administered on days 1, 4, and 8).</description>
    <arm_group_label>4-sites, 1-week without HRIG</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Rabies vaccines + Rabies immunoglobulins</intervention_name>
    <description>12 doses of the PCEC rabies vaccine, administered ID (0.1mL for each injection) to adults only, according to the &quot;4-sites, 1-week&quot; regimen (i.e. 4 doses of vaccine; in both deltoids and anterolateral thigh areas, administered on days 1, 4, and 8). HRIG will be administered on day 1 (before the first dose of the vaccine) in a dose of 20 IU/kg body weight intramuscularly into the gluteal muscle.</description>
    <arm_group_label>4-sites, 1-week with HRIG</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Rabies vaccine</intervention_name>
    <description>8 doses of the PCEC rabies vaccine, administered ID (0.1ml for each injection) according to the &quot;2-sites, TRC&quot;, updated Thai Red Cross regimen (i.e. 2 doses of vaccine; in both deltoids, administered on days 1, 4, 8, and 29).</description>
    <arm_group_label>2-sites, TRC without HRIG</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Rabies vaccines + Rabies immunoglobulins</intervention_name>
    <description>8 doses of the PCEC rabies vaccine, administered ID (0.1ml for each injection) to adults only, according to the &quot;2-sites, TRC&quot;, updated Thai Red Cross regimen (i.e. 2 doses of vaccine; in both deltoids, administered on days 1, 4, 8, and 29). HRIG will be administered on day 1 (before the first dose of the vaccine) in a dose of 20 IU/kg body weight intramuscularly into the gluteal muscle.</description>
    <arm_group_label>2-sites, TRC with HRIG</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy males and females ≥ 1 years of age

          2. Individuals/ individual's parents or legal guardians who have given written consent

          3. Individuals in good health

          4. Individuals who can comply with study procedures

        Exclusion Criteria:

          1. Behavioral or cognitive impairment or psychiatric disease.

          2. Unable to comprehend and to follow all required study procedures for the whole period
             of the study.

          3. History of illness or with an ongoing illness that may pose additional risk to the
             individual if he/she participates in the study.

          4. Individuals ≥ 1 to ≤ 17 years of age, who have or ever had a malignancy.

          5. Individuals ≥ 18 years of age, who have or who within the last 5 years, have had a
             malignancy (excluding nonmelanotic skin cancer) or lymphoproliferative disorder.

          6. Known or suspected impairment of the immune system (including but not limited to HIV,
             autoimmune disorders, immunosuppressive therapy as applicable).

          7. Female of childbearing potential who has not used any of the &quot;acceptable contraceptive
             methods&quot; for at least 2 months prior to study entry.

          8. Female of childbearing potential, refusal to use an &quot;acceptable birth control method&quot;
             through day 50.

          9. Female of childbearing potential, with a positive pregnancy test prior to enrollment.

         10. Received blood, blood products and/or plasma derivatives or any parenteral
             immunoglobulin preparation in the previous 12 weeks.

         11. Allergic to any of the vaccine components.

         12. Allergic to any of the human rabies immunoglobulin components.

         13. Contraindication or precaution against rabies vaccination.

         14. Contraindication or precaution against man rabies immunoglobulin administration.

         15. Planning to receive anti-malaria medications (e.g. Mefloquine) 14 days prior to day 1
             vaccination through day 50.

         16. Participating in any clinical trial with another investigational product 30 days prior
             to first study visit or intent to participate in another clinical study at any time
             during the conduct of this study.

         17. Received any other vaccines within 14 days (for inactivated vaccines) or 28 days (for
             live vaccines) prior to enrollment in this study or who are planning to receive any
             vaccine within 28 days from the study vaccines.

         18. Body temperature ≥ 38.0°C (≥ 100.4°F) within 3 days of intended study vaccination.

         19. Received rabies vaccines or rabies immunoglobulin or have been exposed to rabies.

         20. Part of the study personnel or immediate family members of study personnel conducting
             this study.

         21. Current or history of drug or alcohol abuse within the past 2 years.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Vaccines</last_name>
    <role>Study Chair</role>
    <affiliation>Novartis Vaccines</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>4, De La Salle Health Sciences Institute</name>
      <address>
        <city>Cavite</city>
        <zip>4114</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1, Research Institute for Tropical Medicine</name>
      <address>
        <city>Muntinlupa</city>
        <zip>1781</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>2, Asian Hospital and Medical Center</name>
      <address>
        <city>Muntinlupa</city>
        <zip>1781</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>3, Research Institute for Tropical Medicine</name>
      <address>
        <city>Muntinlupa</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>11, Infectious Diseases Unit, Department of Pediatrics, Phramongkutklao hospital</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>12, Department of Tropical Pediatrics, Faculty of Tropical Medicine, Mahidol University</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Philippines</country>
    <country>Thailand</country>
  </location_countries>
  <link>
    <url>https://www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=15207</url>
    <description>Results for V49_30 from Novartis Clinical Trials Website</description>
  </link>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 24, 2014</study_first_submitted>
  <study_first_submitted_qc>June 26, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2014</study_first_posted>
  <results_first_submitted>August 18, 2016</results_first_submitted>
  <results_first_submitted_qc>February 21, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 7, 2017</results_first_posted>
  <last_update_submitted>February 21, 2017</last_update_submitted>
  <last_update_submitted_qc>February 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rabies vaccines</keyword>
  <keyword>intradermal</keyword>
  <keyword>human rabies immunoglobulins</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rabies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>All enrolled subjects were included in the trial.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>4-sites, 1-week WITHOUT HRIG</title>
          <description>12 doses of the PCEC rabies vaccine, administered ID (0.1mL for each injection) according to the “4-sites, 1-week” regimen</description>
        </group>
        <group group_id="P2">
          <title>4-sites, 1-week WITH HRIG</title>
          <description>12 doses of the PCEC rabies vaccine, administered ID (0.1mL for each injection) to adults only, according to the “4-sites, 1-week” regimen HRIG administered on day 1 (before the first dose of the vaccine) in a dose of 20 IU/kg body weight intramuscularly</description>
        </group>
        <group group_id="P3">
          <title>2-sites, TRC WITHOUT HRIG</title>
          <description>8 doses of the PCEC rabies vaccine, administered ID (0.1ml for each injection) according to the “2-sites, TRC”, updated Thai Red Cross regimen</description>
        </group>
        <group group_id="P4">
          <title>2-sites, TRC WITH HRIG</title>
          <description>8 doses of the PCEC rabies vaccine, administered ID (0.1ml for each injection) to adults only, according to the “2-sites, TRC”, updated Thai Red Cross regimen. HRIG administered on day 1 (before the first dose of the vaccine) in a dose of 20 IU/kg body weight intramuscularly</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="355"/>
                <participants group_id="P2" count="88"/>
                <participants group_id="P3" count="354"/>
                <participants group_id="P4" count="88"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="350"/>
                <participants group_id="P2" count="86"/>
                <participants group_id="P3" count="351"/>
                <participants group_id="P4" count="88"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>ADMINISTRATIVE REASON</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>OTHER</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>4-sites, 1-week WITHOUT HRIG</title>
          <description>12 doses of the PCEC rabies vaccine, administered ID (0.1mL for each injection) according to the “4-sites, 1-week” regimen</description>
        </group>
        <group group_id="B2">
          <title>4-sites, 1-week WITH HRIG</title>
          <description>12 doses of the PCEC rabies vaccine, administered ID (0.1mL for each injection) to adults only, according to the “4-sites, 1-week” regimen HRIG administered on day 1 (before the first dose of the vaccine) in a dose of 20 IU/kg body weight</description>
        </group>
        <group group_id="B3">
          <title>2-sites, TRC WITHOUT HRIG</title>
          <description>8 doses of the PCEC rabies vaccine, administered ID (0.1ml for each injection) according to the “2-sites, TRC”, updated Thai Red Cross regimen.</description>
        </group>
        <group group_id="B4">
          <title>2-sites, TRC WITH HRIG</title>
          <description>8 doses of the PCEC rabies vaccine, administered ID (0.1ml for each injection) to adults only, according to the “2-sites, TRC”, updated Thai Red Cross regimen. HRIG administered on day 1 (before the first dose of the vaccine) in a dose of 20 IU/kg body weight intramuscularly</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="355"/>
            <count group_id="B2" value="88"/>
            <count group_id="B3" value="354"/>
            <count group_id="B4" value="88"/>
            <count group_id="B5" value="885"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>year</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20.0" spread="15.0"/>
                    <measurement group_id="B2" value="32.7" spread="10.8"/>
                    <measurement group_id="B3" value="20.6" spread="15.1"/>
                    <measurement group_id="B4" value="34.4" spread="11.2"/>
                    <measurement group_id="B5" value="22.9" spread="15.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>FEMALE</title>
                  <measurement_list>
                    <measurement group_id="B1" value="202"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="179"/>
                    <measurement group_id="B4" value="51"/>
                    <measurement group_id="B5" value="476"/>
                  </measurement_list>
                </category>
                <category>
                  <title>MALE</title>
                  <measurement_list>
                    <measurement group_id="B1" value="153"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="175"/>
                    <measurement group_id="B4" value="37"/>
                    <measurement group_id="B5" value="409"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentages of Subjects With RVNA Titer &gt;= 0.5 and Vaccine Group Differences (&quot;4-sites, 1-week&quot; to That of &quot;2-sites, TRC&quot; ID PEP Regimen of the PCEC Rabies Vaccine With or Without HRIG Administration)</title>
        <description>Vaccine group differences are calculated assuming a binomial distribution and the associated confidence interval for the differences in percentage was based on M-N method.
Non-inferiority of the immune response of the new &quot;4-sites, 1-week&quot; ID PEP regimen of the PCEC vaccine, with or without HRIG administration, to that of the currently recommended &quot;2-sites, TRC&quot; ID PEP regimen of the PCEC rabies vaccine with or without HRIG administration, as measured by the percentage of subjects with RVNA titer ≥ 0.5 IU/ml at day 50 in the whole study population.</description>
        <time_frame>Study day 50 (D50)</time_frame>
        <population>Per Protocol Set (PPS): all subjects who correctly receive the vaccine doses, provided immunogenicity data at the relevant time points and were not excluded due to reasons defined prior to the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>TOTAL 4-sites, 1-week</title>
            <description>12 doses of the PCEC rabies vaccine, administered ID (0.1mL for each injection) to adults only, according to the “4-sites, 1-week” regimen with and without HRIG administered on day 1</description>
          </group>
          <group group_id="O2">
            <title>TOTAL 2-sites, TRC</title>
            <description>8 doses of the PCEC rabies vaccine, administered ID (0.1ml for each injection) to adults only, according to the “2-sites, TRC”, updated Thai Red Cross regimen, with or without HRIG administered on day 1</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects With RVNA Titer &gt;= 0.5 and Vaccine Group Differences (&quot;4-sites, 1-week&quot; to That of &quot;2-sites, TRC&quot; ID PEP Regimen of the PCEC Rabies Vaccine With or Without HRIG Administration)</title>
          <description>Vaccine group differences are calculated assuming a binomial distribution and the associated confidence interval for the differences in percentage was based on M-N method.
Non-inferiority of the immune response of the new &quot;4-sites, 1-week&quot; ID PEP regimen of the PCEC vaccine, with or without HRIG administration, to that of the currently recommended &quot;2-sites, TRC&quot; ID PEP regimen of the PCEC rabies vaccine with or without HRIG administration, as measured by the percentage of subjects with RVNA titer ≥ 0.5 IU/ml at day 50 in the whole study population.</description>
          <population>Per Protocol Set (PPS): all subjects who correctly receive the vaccine doses, provided immunogenicity data at the relevant time points and were not excluded due to reasons defined prior to the analysis.</population>
          <units>Percentages of Subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="357"/>
                <count group_id="O2" value="350"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99" lower_limit="98" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="99" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority in immune response of the “4-sites, 1-week” (4-4-4-0-0) ID PEP regimen compared to the currently recommended “2-sites TRC” (2-2-2-0-2) ID PEP regimen, with or without HRIG, will be established If the lower bound of the two sided 95% confidence interval around the differences of the percentage of subject with RVNA titer ≥ 0.5 IU/ml at day 50 is &gt; -0.05 (non-inferiority margin).</non_inferiority_desc>
            <param_type>Protection Rate Differences</param_type>
            <param_value>-1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.4</ci_lower_limit>
            <ci_upper_limit>0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Rabies Virus Neutralizing Antibody (RVNA) Concentration and Between-group (2 ID Rabies Vaccine Regimens (4-sites, 1-week and 2-sites, TRC) With or Without HRIG) Ratio of GMCs</title>
        <description>Immunogenicity was assessed in terms of Geometric Mean Rabies Virus Neutralizing Antibody (RVNA) Concentration in Children and Adult Subjects, ≥ 1 Years of Age at day 50 The GMCs, GMRs (i.e., within group ratio) and associated two sided 95% confidence intervals for each group were computed by exponentiating (base 10) of the least square means of the logarithmically transformed (base 10) concentration (and their differences) and the 95% CIs obtained from an Analysis of variance (ANOVA) with vaccine regimen, age strata and center as factors.
Non-inferiority of the immune response between the 2 ID rabies vaccine regimens (4-sites, 1-week and 2-sites, TRC) with or without HRIG administration as measured by RVNA GMCs at day 50 in the whole study population.</description>
        <time_frame>Study Day 50</time_frame>
        <population>Per Protocol Set (PPS): all subjects who correctly receive the vaccine doses, provided immunogenicity data at the relevant time points and were not excluded due to reasons defined prior to the analysis</population>
        <group_list>
          <group group_id="O1">
            <title>TOTAL 4-sites, 1-week</title>
            <description>12 doses of the PCEC rabies vaccine, administered ID (0.1mL for each injection) according to the “4-sites, 1-week” regimen (i.e. 4 doses of vaccine; in both deltoids and anterolateral thigh areas, administered on days 1, 4, and 8) with or without HRIG administration on day 1</description>
          </group>
          <group group_id="O2">
            <title>TOTAL 2-sites, TRC</title>
            <description>8 doses of the PCEC rabies vaccine, administered ID (0.1ml for each injection) to adults only, according to the “2-sites, TRC”, updated Thai Red Cross regimen, with or without HRIG administered on day 1</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Rabies Virus Neutralizing Antibody (RVNA) Concentration and Between-group (2 ID Rabies Vaccine Regimens (4-sites, 1-week and 2-sites, TRC) With or Without HRIG) Ratio of GMCs</title>
          <description>Immunogenicity was assessed in terms of Geometric Mean Rabies Virus Neutralizing Antibody (RVNA) Concentration in Children and Adult Subjects, ≥ 1 Years of Age at day 50 The GMCs, GMRs (i.e., within group ratio) and associated two sided 95% confidence intervals for each group were computed by exponentiating (base 10) of the least square means of the logarithmically transformed (base 10) concentration (and their differences) and the 95% CIs obtained from an Analysis of variance (ANOVA) with vaccine regimen, age strata and center as factors.
Non-inferiority of the immune response between the 2 ID rabies vaccine regimens (4-sites, 1-week and 2-sites, TRC) with or without HRIG administration as measured by RVNA GMCs at day 50 in the whole study population.</description>
          <population>Per Protocol Set (PPS): all subjects who correctly receive the vaccine doses, provided immunogenicity data at the relevant time points and were not excluded due to reasons defined prior to the analysis</population>
          <units>IU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="357"/>
                <count group_id="O2" value="350"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.58" lower_limit="4.15" upper_limit="5.06"/>
                    <measurement group_id="O2" value="10" lower_limit="9.29" upper_limit="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The investigational regimen 4-sites, 1-week” ID PEP will be declared as non-inferior to currently recommended “2-sites TRC” ID PEP regimen if the lower bound of the two sided 95% confidence interval around of the observed GMC ratio is greater than 0.667.</non_inferiority_desc>
            <param_type>Vaccine Group Ratios</param_type>
            <param_value>0.46</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.37</ci_lower_limit>
            <ci_upper_limit>0.58</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Rabies Virus Neutralizing Antibody Concentration at Days 8, 15, 91, 181 and 366 &amp; Between-group (2 ID Rabies Vaccine Regimens (4-sites,1-week &amp; 2-sites, TRC) With or Without HRIG) Ratio of GMCs in Children &amp; Adult Subjects,≥ 1 Years of Age</title>
        <description>Immunogenicity was assessed in terms of the Geometric Mean Rabies Virus Neutralizing Antibody (RVNA) Concentration at Days 8, 15, 91, 181 and 366 in Children and Adult Subjects, ≥ 1 Years of Age The GMCs, GMRs (i.e., within group ratio) and associated two sided 95% confidence intervals for each group were computed by exponentiating (base 10) of the least square means of the logarithmically transformed (base 10) concentration (and their differences) and the 95% CIs obtained from an Analysis of variance (ANOVA) with vaccine regimen, age strata and center as factors.
Non-inferiority of the immune response between the 2 ID rabies vaccine regimens (4-sites, 1-week and 2-sites, TRC) with or without HRIG administration as measured by RVNA GMCs at day 50 in the whole study population.</description>
        <time_frame>At Days 8, 15, 91, 181 and 366</time_frame>
        <population>Per Protocol Set (PPS): all subjects who correctly receive the vaccine doses, provided immunogenicity data at the relevant time points and were not excluded due to reasons defined prior to the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>TOTAL 4-sites, 1-week</title>
            <description>12 doses of the PCEC rabies vaccine, administered ID (0.1mL for each injection) according to the “4-sites, 1-week” regimen (i.e. 4 doses of vaccine; in both deltoids and anterolateral thigh areas, administered on days 1, 4, and 8) with or without HRIG administration on day 1</description>
          </group>
          <group group_id="O2">
            <title>TOTAL 2-sites, TRC</title>
            <description>8 doses of the PCEC rabies vaccine, administered ID (0.1ml for each injection) to adults only, according to the “2-sites, TRC”, updated Thai Red Cross regimen, with or without HRIG administered on day 1</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Rabies Virus Neutralizing Antibody Concentration at Days 8, 15, 91, 181 and 366 &amp; Between-group (2 ID Rabies Vaccine Regimens (4-sites,1-week &amp; 2-sites, TRC) With or Without HRIG) Ratio of GMCs in Children &amp; Adult Subjects,≥ 1 Years of Age</title>
          <description>Immunogenicity was assessed in terms of the Geometric Mean Rabies Virus Neutralizing Antibody (RVNA) Concentration at Days 8, 15, 91, 181 and 366 in Children and Adult Subjects, ≥ 1 Years of Age The GMCs, GMRs (i.e., within group ratio) and associated two sided 95% confidence intervals for each group were computed by exponentiating (base 10) of the least square means of the logarithmically transformed (base 10) concentration (and their differences) and the 95% CIs obtained from an Analysis of variance (ANOVA) with vaccine regimen, age strata and center as factors.
Non-inferiority of the immune response between the 2 ID rabies vaccine regimens (4-sites, 1-week and 2-sites, TRC) with or without HRIG administration as measured by RVNA GMCs at day 50 in the whole study population.</description>
          <population>Per Protocol Set (PPS): all subjects who correctly receive the vaccine doses, provided immunogenicity data at the relevant time points and were not excluded due to reasons defined prior to the analysis.</population>
          <units>IU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="363"/>
                <count group_id="O2" value="362"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 8 (N= 363, 362)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.23" lower_limit="0.21" upper_limit="0.25"/>
                    <measurement group_id="O2" value="0.14" lower_limit="0.13" upper_limit="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15 (N= 357, 361)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18" lower_limit="17" upper_limit="20"/>
                    <measurement group_id="O2" value="12" lower_limit="10" upper_limit="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 91 (N= 358, 362)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.32" lower_limit="2.09" upper_limit="2.56"/>
                    <measurement group_id="O2" value="3.68" lower_limit="3.32" upper_limit="4.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 181 (N= 357, 360)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.59" lower_limit="1.41" upper_limit="1.78"/>
                    <measurement group_id="O2" value="1.44" lower_limit="1.28" upper_limit="1.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 366 (N= 356, 352)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.59" lower_limit="1.41" upper_limit="1.79"/>
                    <measurement group_id="O2" value="1.14" lower_limit="1.01" upper_limit="1.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The investigational regimen 4-sites, 1-week” ID PEP will be declared as non-inferior to currently recommended “2-sites TRC” ID PEP regimen if the lower bound of the two sided 95% confidence interval around of the observed GMC ratio is greater than 0.667 (Day 8)</non_inferiority_desc>
            <param_type>Vaccine Group Ratios</param_type>
            <param_value>1.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.84</ci_lower_limit>
            <ci_upper_limit>1.29</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The investigational regimen 4-sites, 1-week” ID PEP will be declared as non-inferior to currently recommended “2-sites TRC” ID PEP regimen if the lower bound of the two sided 95% confidence interval around of the observed GMC ratio is greater than 0.667 (Day 15)</non_inferiority_desc>
            <param_type>Vaccine Group Ratios</param_type>
            <param_value>1.68</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.35</ci_lower_limit>
            <ci_upper_limit>2.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The investigational regimen 4-sites, 1-week” ID PEP will be declared as non-inferior to currently recommended “2-sites TRC” ID PEP regimen if the lower bound of the two sided 95% confidence interval around of the observed GMC ratio is greater than 0.667 (Day 91).</non_inferiority_desc>
            <param_type>Vaccine Group Ratios</param_type>
            <param_value>0.68</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.54</ci_lower_limit>
            <ci_upper_limit>0.85</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The investigational regimen 4-sites, 1-week” ID PEP will be declared as non-inferior to currently recommended “2-sites TRC” ID PEP regimen if the lower bound of the two sided 95% confidence interval around of the observed GMC ratio is greater than 0.667 (Day 181)</non_inferiority_desc>
            <param_type>Vaccine Group Ratios</param_type>
            <param_value>1.22</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.94</ci_lower_limit>
            <ci_upper_limit>1.59</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The investigational regimen 4-sites, 1-week” ID PEP will be declared as non-inferior to currently recommended “2-sites TRC” ID PEP regimen if the lower bound of the two sided 95% confidence interval around of the observed GMC ratio is greater than 0.667 (Day 366)</non_inferiority_desc>
            <param_type>Vaccine Group Ratios</param_type>
            <param_value>1.67</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.27</ci_lower_limit>
            <ci_upper_limit>2.19</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects With Anti-RVNA Titer ≥0.5 IU/mL at Days 8, 15, 91, 181 and 366 in Children and Adult Subjects and Vaccine Group Differences (2 ID Rabies Vaccine Regimens (4-sites, 1-week and 2-sites, TRC), With or Without HRIG), ≥ 1 Years of Age</title>
        <description>Vaccine group differences are calculated assuming a binomial distribution and the associated confidence interval for the differences in percentage was based on M-N method.
RVNA percentage of subjects with RVNA titer ≥ 0.5 IU/mL at study days 8, 15, 91, 181, and 366 following administration of the 2 ID rabies vaccine regimens (4-sites, 1-week and 2-sites, TRC), with or without HRIG, in the whole study population.</description>
        <time_frame>At Days 8, 15, 91, 181 and 366</time_frame>
        <population>Per Protocol Set (PPS): all subjects who correctly receive the vaccine doses, provided immunogenicity data at the relevant time points and were not excluded due to reasons defined prior to the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>TOTAL 4-sites, 1-week</title>
            <description>12 doses of the PCEC rabies vaccine, administered ID (0.1mL for each injection) according to the “4-sites, 1-week” regimen (i.e. 4 doses of vaccine; in both deltoids and anterolateral thigh areas, administered on days 1, 4, and 8) with or without HRIG administration on day 1</description>
          </group>
          <group group_id="O2">
            <title>TOTAL 2-sites, TRC</title>
            <description>8 doses of the PCEC rabies vaccine, administered ID (0.1ml for each injection) to adults only, according to the “2-sites, TRC”, updated Thai Red Cross regimen, with or without HRIG administered on day 1</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects With Anti-RVNA Titer ≥0.5 IU/mL at Days 8, 15, 91, 181 and 366 in Children and Adult Subjects and Vaccine Group Differences (2 ID Rabies Vaccine Regimens (4-sites, 1-week and 2-sites, TRC), With or Without HRIG), ≥ 1 Years of Age</title>
          <description>Vaccine group differences are calculated assuming a binomial distribution and the associated confidence interval for the differences in percentage was based on M-N method.
RVNA percentage of subjects with RVNA titer ≥ 0.5 IU/mL at study days 8, 15, 91, 181, and 366 following administration of the 2 ID rabies vaccine regimens (4-sites, 1-week and 2-sites, TRC), with or without HRIG, in the whole study population.</description>
          <population>Per Protocol Set (PPS): all subjects who correctly receive the vaccine doses, provided immunogenicity data at the relevant time points and were not excluded due to reasons defined prior to the analysis.</population>
          <units>Percentages of Subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="363"/>
                <count group_id="O2" value="362"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 8 (N= 363, 362)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18" lower_limit="15" upper_limit="23"/>
                    <measurement group_id="O2" value="10" lower_limit="7" upper_limit="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15 (N= 357, 361)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="99" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="98" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 91 (N= 358, 362)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96" lower_limit="94" upper_limit="98"/>
                    <measurement group_id="O2" value="99" lower_limit="98" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 181 (N= 357, 360)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93" lower_limit="90" upper_limit="95"/>
                    <measurement group_id="O2" value="93" lower_limit="90" upper_limit="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 366 (N= 356, 352)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90" lower_limit="86" upper_limit="93"/>
                    <measurement group_id="O2" value="83" lower_limit="79" upper_limit="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority in immune response of the “4-sites, 1-week” (4-4-4-0-0) ID PEP regimen compared to the currently recommended “2-sites TRC” (2-2-2-0-2) ID PEP regimen, with or without HRIG, will be established If the lower bound of the two sided 95% confidence interval around the differences of the percentage of subject with RVNA titer ≥ 0.5 IU/ml at Day 8 is &gt; -0.05 (non-inferiority margin).</non_inferiority_desc>
            <param_type>Protection Rate Differences</param_type>
            <param_value>9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.8</ci_lower_limit>
            <ci_upper_limit>13.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority in immune response of the “4-sites, 1-week” (4-4-4-0-0) ID PEP regimen compared to the currently recommended “2-sites TRC” (2-2-2-0-2) ID PEP regimen, with or without HRIG, will be established If the lower bound of the two sided 95% confidence interval around the differences of the percentage of subject with RVNA titer ≥ 0.5 IU/ml at Day 15 is &gt; -0.05 (non-inferiority margin).</non_inferiority_desc>
            <param_type>Protection Rate Differences</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1</ci_lower_limit>
            <ci_upper_limit>1.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority in immune response of the “4-sites, 1-week” (4-4-4-0-0) ID PEP regimen compared to the currently recommended “2-sites TRC” (2-2-2-0-2) ID PEP regimen, with or without HRIG, will be established If the lower bound of the two sided 95% confidence interval around the differences of the percentage of subject with RVNA titer ≥ 0.5 IU/ml at Day 91 is &gt; -0.05 (non-inferiority margin).</non_inferiority_desc>
            <param_type>Protection Rate Differences</param_type>
            <param_value>-3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6</ci_lower_limit>
            <ci_upper_limit>-1.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority in immune response of the “4-sites, 1-week” (4-4-4-0-0) ID PEP regimen compared to the currently recommended “2-sites TRC” (2-2-2-0-2) ID PEP regimen, with or without HRIG, will be established If the lower bound of the two sided 95% confidence interval around the differences of the percentage of subject with RVNA titer ≥ 0.5 IU/ml at Day 181 is &gt; -0.05 (non-inferiority margin).</non_inferiority_desc>
            <param_type>Protection Rate Differences</param_type>
            <param_value>-1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.5</ci_lower_limit>
            <ci_upper_limit>3.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority in immune response of the “4-sites, 1-week” (4-4-4-0-0) ID PEP regimen compared to the currently recommended “2-sites TRC” (2-2-2-0-2) ID PEP regimen, with or without HRIG, will be established If the lower bound of the two sided 95% confidence interval around the differences of the percentage of subject with RVNA titer ≥ 0.5 IU/ml at Day 366 is &gt; -0.05 (non-inferiority margin).</non_inferiority_desc>
            <param_type>Protection Rate Differences</param_type>
            <param_value>6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.3</ci_lower_limit>
            <ci_upper_limit>11.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Rabies Virus Neutralizing Antibody (RVNA) Concentration and Vaccine Group Differences in Adult Subjects, ≥ 18 Years of Age</title>
        <description>Immunogenicity was assessed in terms of the Geometric Mean Rabies Virus Neutralizing Antibody (RVNA) Concentration at Days 8, 15, 50,91, 181 and 366 in Adult Subjects, ≥ 18 Years of Age.
RVNA GMCs with RVNA titer ≥ 0.5 IU/mL at days 8, 15, 50, 91, 181 and 366 and group differences (4-sites,1-week without HRIG versus 4-sites,1-week with HRIG; 4-sites,1-week with HRIG versus 2-sites,TRC with HRIG; 4-sites,1-week without HRIG versus 2-sites, TRC without HRIG)</description>
        <time_frame>At Days 8, 15, 50, 91, 181 and 366</time_frame>
        <population>Per Protocol Set (PPS): all subjects who correctly receive the vaccine doses, provided immunogenicity data at the relevant time points and were not excluded due to reasons defined prior to the analysis. This outcome measure is applicable only for the 4-sites, 1-week with HRIG and 4-sites, 1-week without HRIG Groups.</population>
        <group_list>
          <group group_id="O1">
            <title>4-sites, 1-week WITH HRIG</title>
            <description>12 doses of the PCEC rabies vaccine, administered ID (0.1mL for each injection) to adults only, according to the “4-sites, 1-week” regimen with HRIG administered on day 1 (before the first dose of the vaccine) in a dose of 20 IU/kg body weight</description>
          </group>
          <group group_id="O2">
            <title>4-sites, 1-week WITHOUT HRIG</title>
            <description>12 doses of the PCEC rabies vaccine, administered ID (0.1mL for each injection) according to the “4-sites, 1-week” regimen</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Rabies Virus Neutralizing Antibody (RVNA) Concentration and Vaccine Group Differences in Adult Subjects, ≥ 18 Years of Age</title>
          <description>Immunogenicity was assessed in terms of the Geometric Mean Rabies Virus Neutralizing Antibody (RVNA) Concentration at Days 8, 15, 50,91, 181 and 366 in Adult Subjects, ≥ 18 Years of Age.
RVNA GMCs with RVNA titer ≥ 0.5 IU/mL at days 8, 15, 50, 91, 181 and 366 and group differences (4-sites,1-week without HRIG versus 4-sites,1-week with HRIG; 4-sites,1-week with HRIG versus 2-sites,TRC with HRIG; 4-sites,1-week without HRIG versus 2-sites, TRC without HRIG)</description>
          <population>Per Protocol Set (PPS): all subjects who correctly receive the vaccine doses, provided immunogenicity data at the relevant time points and were not excluded due to reasons defined prior to the analysis. This outcome measure is applicable only for the 4-sites, 1-week with HRIG and 4-sites, 1-week without HRIG Groups.</population>
          <units>IU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 8 (N= 66, 150)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.21" lower_limit="0.17" upper_limit="0.26"/>
                    <measurement group_id="O2" value="0.15" lower_limit="0.13" upper_limit="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15 (N= 65, 146)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13" lower_limit="11" upper_limit="15"/>
                    <measurement group_id="O2" value="15" lower_limit="13" upper_limit="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 50 (N= 65, 146)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.97" lower_limit="1.6" upper_limit="2.43"/>
                    <measurement group_id="O2" value="4.47" lower_limit="3.9" upper_limit="5.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 91 (N= 65, 149)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.01" lower_limit="0.81" upper_limit="1.27"/>
                    <measurement group_id="O2" value="2.28" lower_limit="1.96" upper_limit="2.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 181 (N= 65, 146)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.88" lower_limit="0.67" upper_limit="1.14"/>
                    <measurement group_id="O2" value="1.92" lower_limit="1.61" upper_limit="2.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 366 (N= 65, 145)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.68" lower_limit="0.53" upper_limit="0.88"/>
                    <measurement group_id="O2" value="1.42" lower_limit="1.19" upper_limit="1.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority in immune response of the “4-sites, 1-week” (4-4-4-0-0) ID PEP regimen of the PCEC vaccine, with HRIG administration, compared to that of the new “4-sites, 1-week” (4-4-4-0-0) ID PEP regimen of the PCEC vaccine, without HRIG administration, in adult subjects will be established if the lower bound of the two sided 95% confidence interval around the differences of the percentage of subject with RVNA titer ≥ 0.5 IU/ml at Day 8 is &gt; -0.05 (non-inferiority margin).</non_inferiority_desc>
            <param_type>Protection Rate Differences</param_type>
            <param_value>-11</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-19.6</ci_lower_limit>
            <ci_upper_limit>-1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority in immune response of the “4-sites, 1-week” (4-4-4-0-0) ID PEP regimen of the PCEC vaccine, with HRIG administration, compared to that of the new “4-sites, 1-week” (4-4-4-0-0) ID PEP regimen of the PCEC vaccine, without HRIG administration, in adult subjects will be established if the lower bound of the two sided 95% confidence interval around the differences of the percentage of subject with RVNA titer ≥ 0.5 IU/ml at Day 15 is &gt; -0.05 (non-inferiority margin).</non_inferiority_desc>
            <param_type>Protection Rate Differences</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.6</ci_lower_limit>
            <ci_upper_limit>2.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority in immune response of the “4-sites, 1-week” (4-4-4-0-0) ID PEP regimen of the PCEC vaccine, with HRIG administration, compared to that of the new “4-sites, 1-week” (4-4-4-0-0) ID PEP regimen of the PCEC vaccine, without HRIG administration, in adult subjects will be established if the lower bound of the two sided 95% confidence interval around the differences of the percentage of subject with RVNA titer ≥ 0.5 IU/ml at Day 91 is &gt; -0.05 (non-inferiority margin).</non_inferiority_desc>
            <param_type>Protection Rate Differences</param_type>
            <param_value>-15</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-26</ci_lower_limit>
            <ci_upper_limit>-7.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority in immune response of the “4-sites, 1-week” (4-4-4-0-0) ID PEP regimen of the PCEC vaccine, with HRIG administration, compared to that of the new “4-sites, 1-week” (4-4-4-0-0) ID PEP regimen of the PCEC vaccine, without HRIG administration, in adult subjects will be established if the lower bound of the two sided 95% confidence interval around the differences of the percentage of subject with RVNA titer ≥ 0.5 IU/ml at Day 181 is &gt; -0.05 (non-inferiority margin).</non_inferiority_desc>
            <param_type>Protection Rate Differences</param_type>
            <param_value>-17</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-29</ci_lower_limit>
            <ci_upper_limit>-7.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority in immune response of the “4-sites, 1-week” (4-4-4-0-0) ID PEP regimen of the PCEC vaccine, with HRIG administration, compared to that of the new “4-sites, 1-week” (4-4-4-0-0) ID PEP regimen of the PCEC vaccine, without HRIG administration, in adult subjects will be established if the lower bound of the two sided 95% confidence interval around the differences of the percentage of subject with RVNA titer ≥ 0.5 IU/ml at Day 366 is &gt; -0.05 (non-inferiority margin).</non_inferiority_desc>
            <param_type>Protection Rate Differences</param_type>
            <param_value>-25</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-37.8</ci_lower_limit>
            <ci_upper_limit>-13.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects With Anti-RVNA Titer ≥0.5 IU/mL in Adult Subjects, ≥ 18 Years of Age</title>
        <description>Immunogenicity was assessed in terms of the Percentages of Subjects With Anti-RVNA concentration ≥0.5 IU/mL at Days 8, 15, 50, 91, 181 and 366 in Adult Subjects, ≥ 18 Years of Age.
Percentage of subjects with RVNA titer ≥ 0.5 IU/mL at days 8, 15, 50, 91, 181 and 366 and group differences (4-sites,1-week without HRIG versus 4-sites,1-week with HRIG; 4-sites,1-week with HRIG versus 2-sites,TRC with HRIG; 4-sites,1-week without HRIG versus 2-sites, TRC without HRIG)</description>
        <time_frame>At Days 8, 15,50, 91, 181 and 366</time_frame>
        <population>Per Protocol Set (PPS): all subjects who correctly receive the vaccine doses, provided immunogenicity data at the relevant time points and were not excluded due to reasons defined prior to the analysis. This outcome measure is applicable only for the 4-sites, 1-week with HRIG and 4-sites, 1-week without HRIG Groups.</population>
        <group_list>
          <group group_id="O1">
            <title>4-sites, 1-week WITH HRIG</title>
            <description>12 doses of the PCEC rabies vaccine, administered ID (0.1mL for each injection) to adults only, according to the “4-sites, 1-week” regimen HRIG administered on day 1 (before the first dose of the vaccine) in a dose of 20 IU/kg body weight</description>
          </group>
          <group group_id="O2">
            <title>4-sites, 1-week WITHOUT HRIG</title>
            <description>12 doses of the PCEC rabies vaccine, administered ID (0.1mL for each injection) according to the “4-sites, 1-week” regimen</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects With Anti-RVNA Titer ≥0.5 IU/mL in Adult Subjects, ≥ 18 Years of Age</title>
          <description>Immunogenicity was assessed in terms of the Percentages of Subjects With Anti-RVNA concentration ≥0.5 IU/mL at Days 8, 15, 50, 91, 181 and 366 in Adult Subjects, ≥ 18 Years of Age.
Percentage of subjects with RVNA titer ≥ 0.5 IU/mL at days 8, 15, 50, 91, 181 and 366 and group differences (4-sites,1-week without HRIG versus 4-sites,1-week with HRIG; 4-sites,1-week with HRIG versus 2-sites,TRC with HRIG; 4-sites,1-week without HRIG versus 2-sites, TRC without HRIG)</description>
          <population>Per Protocol Set (PPS): all subjects who correctly receive the vaccine doses, provided immunogenicity data at the relevant time points and were not excluded due to reasons defined prior to the analysis. This outcome measure is applicable only for the 4-sites, 1-week with HRIG and 4-sites, 1-week without HRIG Groups.</population>
          <units>Percentages of Subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (N= 66, 151)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="5"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8 (N= 66, 150)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8" lower_limit="3" upper_limit="17"/>
                    <measurement group_id="O2" value="19" lower_limit="13" upper_limit="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15 (N= 65, 146)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="94" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="98" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 50 (N= 65, 146)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95" lower_limit="87" upper_limit="99"/>
                    <measurement group_id="O2" value="100" lower_limit="98" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 91 (N= 65, 149)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83" lower_limit="72" upper_limit="91"/>
                    <measurement group_id="O2" value="98" lower_limit="94" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 181 (N= 65, 146)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77" lower_limit="65" upper_limit="86"/>
                    <measurement group_id="O2" value="94" lower_limit="89" upper_limit="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 366 (N= 65, 145)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66" lower_limit="53" upper_limit="77"/>
                    <measurement group_id="O2" value="91" lower_limit="85" upper_limit="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Rabies Virus Neutralizing Antibody (RVNA) Concentration in Children and Adult Subjects, ≥ 1 Years of Age</title>
        <description>Immunogenicity was assessed in terms of the Geometric Mean Rabies Virus Neutralizing Antibody (RVNA) Concentration at Days 8, 15, 50, 91, 181 and 366 in Children and Adult Subjects, ≥ 1 Years of Age</description>
        <time_frame>At Days 8, 15, 50, 91, 181 and 366</time_frame>
        <population>Per Protocol Set (PPS): all subjects who correctly receive the vaccine doses, provided immunogenicity data at the relevant time points and were not excluded due to reasons defined prior to the analysis. This outcome measure is applicable only for the 4-sites, 1-week without HRIG and 2-sites, TRC without HRIG Groups.</population>
        <group_list>
          <group group_id="O1">
            <title>4-sites, 1-week Without HRIG</title>
            <description>12 doses of the PCEC rabies vaccine, administered ID (0.1mL for each injection) according to the “4-sites, 1-week” regimen</description>
          </group>
          <group group_id="O2">
            <title>2-sites, TRC Without HRIG</title>
            <description>8 doses of the PCEC rabies vaccine, administered ID (0.1ml for each injection) according to the “2-sites, TRC”, updated Thai Red Cross regimen.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Rabies Virus Neutralizing Antibody (RVNA) Concentration in Children and Adult Subjects, ≥ 1 Years of Age</title>
          <description>Immunogenicity was assessed in terms of the Geometric Mean Rabies Virus Neutralizing Antibody (RVNA) Concentration at Days 8, 15, 50, 91, 181 and 366 in Children and Adult Subjects, ≥ 1 Years of Age</description>
          <population>Per Protocol Set (PPS): all subjects who correctly receive the vaccine doses, provided immunogenicity data at the relevant time points and were not excluded due to reasons defined prior to the analysis. This outcome measure is applicable only for the 4-sites, 1-week without HRIG and 2-sites, TRC without HRIG Groups.</population>
          <units>IU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="298"/>
                <count group_id="O2" value="290"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (N=298, 290)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" lower_limit="0.05" upper_limit="0.05"/>
                    <measurement group_id="O2" value="0.05" lower_limit="0.05" upper_limit="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8 (N= 297, 290)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.23" lower_limit="0.21" upper_limit="0.25"/>
                    <measurement group_id="O2" value="0.13" lower_limit="0.12" upper_limit="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15 (N= 292, 289)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19" lower_limit="17" upper_limit="21"/>
                    <measurement group_id="O2" value="12" lower_limit="11" upper_limit="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 50 (N= 292, 281)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.04" lower_limit="4.56" upper_limit="5.57"/>
                    <measurement group_id="O2" value="10" lower_limit="9.48" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 91 (N= 293, 290)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.54" lower_limit="2.29" upper_limit="2.82"/>
                    <measurement group_id="O2" value="3.8" lower_limit="3.42" upper_limit="4.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 181 (N= 292, 289)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.73" lower_limit="1.53" upper_limit="1.95"/>
                    <measurement group_id="O2" value="1.5" lower_limit="1.32" upper_limit="1.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 366 (N= 291, 283)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.73" lower_limit="1.53" upper_limit="1.95"/>
                    <measurement group_id="O2" value="1.2" lower_limit="1.06" upper_limit="1.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects With Anti-RVNA Titer ≥0.5 IU/mL in Children and Adult Subjects, ≥ 1 Years of Age</title>
        <description>Immunogenicity was assessed in terms of the Percentages of Subjects With Anti-RVNA concentration ≥0.5 IU/mL at Days 8, 15, 50, 91, 181 and 366 in Children and Adult Subjects, ≥ 1 Years of Age</description>
        <time_frame>At Days 8, 15, 50, 91, 181 and 366</time_frame>
        <population>Per Protocol Set (PPS): all subjects who correctly receive the vaccine doses, provided immunogenicity data at the relevant time points and were not excluded due to reasons defined prior to the analysis. This outcome measure is only applicable for the 4-sites, 1-week without HRIG and 2-sites, TRC without HRIG Groups.</population>
        <group_list>
          <group group_id="O1">
            <title>4-sites, 1-week Without HRIG</title>
            <description>12 doses of the PCEC rabies vaccine, administered ID (0.1mL for each injection) according to the “4-sites, 1-week” regimen</description>
          </group>
          <group group_id="O2">
            <title>2-sites, TRC Without HRIG</title>
            <description>8 doses of the PCEC rabies vaccine, administered ID (0.1ml for each injection) according to the “2-sites, TRC”, updated Thai Red Cross regimen.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects With Anti-RVNA Titer ≥0.5 IU/mL in Children and Adult Subjects, ≥ 1 Years of Age</title>
          <description>Immunogenicity was assessed in terms of the Percentages of Subjects With Anti-RVNA concentration ≥0.5 IU/mL at Days 8, 15, 50, 91, 181 and 366 in Children and Adult Subjects, ≥ 1 Years of Age</description>
          <population>Per Protocol Set (PPS): all subjects who correctly receive the vaccine doses, provided immunogenicity data at the relevant time points and were not excluded due to reasons defined prior to the analysis. This outcome measure is only applicable for the 4-sites, 1-week without HRIG and 2-sites, TRC without HRIG Groups.</population>
          <units>Percentages of Subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="298"/>
                <count group_id="O2" value="290"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 8 (N= 297, 290)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21" lower_limit="16" upper_limit="26"/>
                    <measurement group_id="O2" value="10" lower_limit="7" upper_limit="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15 (N= 292, 289)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="99" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="99" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 50 (N= 292, 281)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="99" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="99" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 91 (N= 293, 290)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99" lower_limit="97" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="98" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 181 (N= 292, 289)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96" lower_limit="93" upper_limit="98"/>
                    <measurement group_id="O2" value="96" lower_limit="92" upper_limit="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 366 (N= 291, 283)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95" lower_limit="92" upper_limit="97"/>
                    <measurement group_id="O2" value="87" lower_limit="82" upper_limit="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Who Reported Solicited Local and Systemic Adverse Events After Any Vaccination</title>
        <description>Number of subjects Who Reported Solicited Local and Systemic Adverse Events After Any Vaccination</description>
        <time_frame>From day 1 to day 3; from day 4 to day 7; from day 8 to day 14; from day 29 to day 35(2-sites, TRC PEP, ID regimen)</time_frame>
        <population>Solicited Safety Set- All subjects in the Exposed Population who provide post vaccination solicited adverse event data. The number of exposed set participants analyzed for safety is different from the Per Protocol Set (PPS) for immunogenicity.</population>
        <group_list>
          <group group_id="O1">
            <title>4-sites, 1-week WITHOUT HRIG</title>
            <description>12 doses of the PCEC rabies vaccine, administered ID (0.1mL for each injection) according to the “4-sites, 1-week” regimen</description>
          </group>
          <group group_id="O2">
            <title>4-sites, 1-week WITH HRIG</title>
            <description>12 doses of the PCEC rabies vaccine, administered ID (0.1mL for each injection) to adults only, according to the “4-sites, 1-week” regimen HRIG administered on day 1 (before the first dose of the vaccine) in a dose of 20 IU/kg body weight</description>
          </group>
          <group group_id="O3">
            <title>2-sites, TRC WITHOUT HRIG</title>
            <description>8 doses of the PCEC rabies vaccine, administered ID (0.1ml for each injection) according to the “2-sites, TRC”, updated Thai Red Cross regimen.</description>
          </group>
          <group group_id="O4">
            <title>2-sites, TRC WITH HRIG</title>
            <description>8 doses of the PCEC rabies vaccine, administered ID (0.1ml for each injection) to adults only, according to the “2-sites, TRC”, updated Thai Red Cross regimen. HRIG administered on day 1 (before the first dose of the vaccine) in a dose of 20 IU/kg body weight intramuscularly</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Who Reported Solicited Local and Systemic Adverse Events After Any Vaccination</title>
          <description>Number of subjects Who Reported Solicited Local and Systemic Adverse Events After Any Vaccination</description>
          <population>Solicited Safety Set- All subjects in the Exposed Population who provide post vaccination solicited adverse event data. The number of exposed set participants analyzed for safety is different from the Per Protocol Set (PPS) for immunogenicity.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="356"/>
                <count group_id="O2" value="85"/>
                <count group_id="O3" value="353"/>
                <count group_id="O4" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Injection site erythema(≥ 1 to ≤ 5 Y); Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="NA">No data as only adults to be enrolled to this group</measurement>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="NA">No data as only adults to be enrolled to this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site erythema(≥ 1 to ≤ 5 Y); Day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="NA">No data as only adults to be enrolled to this group</measurement>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="NA">No data as only adults to be enrolled to this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site erythema(≥ 1 to ≤ 5 Y); Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="NA">No data as only adults to be enrolled to this group</measurement>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="NA">No data as only adults to be enrolled to this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site erythema(≥ 1 to ≤ 5 Y); Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not assessed at Day 29 for this group</measurement>
                    <measurement group_id="O2" value="NA">No data as only adults to be enrolled to this group</measurement>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="NA">No data as only adults to be enrolled to this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site induration(≥ 1 to ≤ 5 Y); Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="NA">No data as only adults to be enrolled to this group</measurement>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="NA">No data as only adults to be enrolled to this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site induration(≥ 1 to ≤ 5 Y); Day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="NA">No data as only adults to be enrolled to this group</measurement>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="NA">No data as only adults to be enrolled to this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site induration(≥ 1 to ≤ 5 Y); Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="NA">No data as only adults to be enrolled to this group</measurement>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="NA">No data as only adults to be enrolled to this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site induration(≥ 1 to ≤ 5 Y); Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not assessed at Day 29 for this group</measurement>
                    <measurement group_id="O2" value="NA">No data as only adults to be enrolled to this group</measurement>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="NA">No data as only adults to be enrolled to this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site swelling (≥ 1 to ≤ 5 Y); Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="NA">No data as only adults to be enrolled to this group</measurement>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="NA">No data as only adults to be enrolled to this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site swelling (≥ 1 to ≤ 5 Y); Day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="NA">No data as only adults to be enrolled to this group</measurement>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="NA">No data as only adults to be enrolled to this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site swelling (≥ 1 to ≤ 5 Y); Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="NA">No data as only adults to be enrolled to this group</measurement>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="NA">No data as only adults to be enrolled to this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site swelling (≥ 1 to ≤ 5 Y); Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not assessed at Day 29 for this group</measurement>
                    <measurement group_id="O2" value="NA">No data as only adults to be enrolled to this group</measurement>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="NA">No data as only adults to be enrolled to this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site erythema (≥ 6 to ≤ 17 Y); Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="NA">No data as only adults to be enrolled to this group</measurement>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="NA">No data as only adults to be enrolled to this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site erythema (≥ 6 to ≤ 17 Y); Day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="NA">No data as only adults to be enrolled to this group</measurement>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="NA">No data as only adults to be enrolled to this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site erythema (≥ 6 to ≤ 17 Y); Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="NA">No data as only adults to be enrolled to this group</measurement>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="NA">No data as only adults to be enrolled to this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site erythema (≥ 6 to ≤ 17 Y); Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not assessed at Day 29 for this group</measurement>
                    <measurement group_id="O2" value="NA">No data as only adults to be enrolled to this group</measurement>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="NA">No data as only adults to be enrolled to this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site induration (≥ 6 to ≤ 17 Y); Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="NA">No data as only adults to be enrolled to this group</measurement>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="NA">No data as only adults to be enrolled to this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site induration (≥ 6 to ≤ 17 Y); Day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="NA">No data as only adults to be enrolled to this group</measurement>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="NA">No data as only adults to be enrolled to this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site induration (≥ 6 to ≤ 17 Y); Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="NA">No data as only adults to be enrolled to this group</measurement>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="NA">No data as only adults to be enrolled to this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site induration (≥ 6 to ≤ 17 Y); Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not assessed at Day 29 for this group</measurement>
                    <measurement group_id="O2" value="NA">No data as only adults to be enrolled to this group</measurement>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="NA">No data as only adults to be enrolled to this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site swelling (≥ 6 to ≤ 17 Y); Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="NA">No data as only adults to be enrolled to this group</measurement>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="NA">No data as only adults to be enrolled to this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site swelling (≥ 6 to ≤ 17 Y); Day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="NA">No data as only adults to be enrolled to this group</measurement>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="NA">No data as only adults to be enrolled to this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site swelling (≥ 6 to ≤ 17 Y); Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="NA">No data as only adults to be enrolled to this group</measurement>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="NA">No data as only adults to be enrolled to this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site swelling (≥ 6 to ≤ 17 Y); Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not assessed at Day 29 for this group</measurement>
                    <measurement group_id="O2" value="NA">No data as only adults to be enrolled to this group</measurement>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="NA">No data as only adults to be enrolled to this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site erythema (≥ 18 Y); Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site erythema (≥ 18 Y); Day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site erythema (≥ 18 Y); Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site erythema (≥ 18 Y); Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not assessed at Day 29 for this group</measurement>
                    <measurement group_id="O2" value="NA">Not assessed at Day 29 for this group</measurement>
                    <measurement group_id="O3" value="27"/>
                    <measurement group_id="O4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site induration (≥ 18 Y); Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site induration (≥ 18 Y); Day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site induration (≥ 18 Y); Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site induration (≥ 18 Y); Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not assessed at Day 29 for this group</measurement>
                    <measurement group_id="O2" value="NA">Not assessed at Day 29 for this group</measurement>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site swelling (≥ 18 Y); Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site swelling (≥ 18 Y); Day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site swelling (≥ 18 Y); Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site swelling (≥ 18 Y); Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not assessed at Day 29 for this group</measurement>
                    <measurement group_id="O2" value="NA">Not assessed at Day 29 for this group</measurement>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change In Eating Habits,( ≥ 1 to ≤ 5 Y); Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="NA">No data as only adults to be enrolled to this group</measurement>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="NA">No data as only adults to be enrolled to this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change In Eating Habits,( ≥ 1 to ≤ 5 Y); Day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="NA">No data as only adults to be enrolled to this group</measurement>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="NA">No data as only adults to be enrolled to this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change In Eating Habits,( ≥ 1 to ≤ 5 Y); Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="NA">No data as only adults to be enrolled to this group</measurement>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="NA">No data as only adults to be enrolled to this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change In Eating Habits,( ≥ 1 to ≤ 5 Y); Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not assessed at Day 29 for this group</measurement>
                    <measurement group_id="O2" value="NA">No data as only adults to be enrolled to this group</measurement>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="NA">No data as only adults to be enrolled to this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleepiness (≥ 1 to ≤ 5 Y); Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="NA">No data as only adults to be enrolled to this group</measurement>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="NA">No data as only adults to be enrolled to this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleepiness (≥ 1 to ≤ 5 Y); Day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="NA">No data as only adults to be enrolled to this group</measurement>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="NA">No data as only adults to be enrolled to this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleepiness (≥ 1 to ≤ 5 Y); Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="NA">No data as only adults to be enrolled to this group</measurement>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="NA">No data as only adults to be enrolled to this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleepiness (≥ 1 to ≤ 5 Y); Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not assessed at Day 29 for this group</measurement>
                    <measurement group_id="O2" value="NA">No data as only adults to be enrolled to this group</measurement>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="NA">No data as only adults to be enrolled to this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting (≥ 1 to ≤ 5 Y); Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="NA">No data as only adults to be enrolled to this group</measurement>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="NA">No data as only adults to be enrolled to this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting (≥ 1 to ≤ 5 Y); Day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="NA">No data as only adults to be enrolled to this group</measurement>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="NA">No data as only adults to be enrolled to this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting (≥ 1 to ≤ 5 Y); Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="NA">No data as only adults to be enrolled to this group</measurement>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="NA">No data as only adults to be enrolled to this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting (≥ 1 to ≤ 5 Y); Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not assessed at Day 29 for this group</measurement>
                    <measurement group_id="O2" value="NA">No data as only adults to be enrolled to this group</measurement>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="NA">No data as only adults to be enrolled to this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea (≥ 1 to ≤ 5 Y); Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="NA">No data as only adults to be enrolled to this group</measurement>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="NA">No data as only adults to be enrolled to this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea (≥ 1 to ≤ 5 Y); Day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="NA">No data as only adults to be enrolled to this group</measurement>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="NA">No data as only adults to be enrolled to this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea (≥ 1 to ≤ 5 Y); Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="NA">No data as only adults to be enrolled to this group</measurement>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="NA">No data as only adults to be enrolled to this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea (≥ 1 to ≤ 5 Y); Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not assessed at Day 29 for this group</measurement>
                    <measurement group_id="O2" value="NA">No data as only adults to be enrolled to this group</measurement>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="NA">No data as only adults to be enrolled to this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability.( ≥ 1 to ≤ 5 Y); Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="NA">No data as only adults to be enrolled to this group</measurement>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="NA">No data as only adults to be enrolled to this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability.( ≥ 1 to ≤ 5 Y); Day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="NA">No data as only adults to be enrolled to this group</measurement>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="NA">No data as only adults to be enrolled to this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability.( ≥ 1 to ≤ 5 Y); Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="NA">No data as only adults to be enrolled to this group</measurement>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="NA">No data as only adults to be enrolled to this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability.( ≥ 1 to ≤ 5 Y); Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not assessed at Day 29 for this group</measurement>
                    <measurement group_id="O2" value="NA">No data as only adults to be enrolled to this group</measurement>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="NA">No data as only adults to be enrolled to this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills(≥ 6 to ≤ 17 Y); Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="NA">No data as only adults to be enrolled to this group</measurement>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="NA">No data as only adults to be enrolled to this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills(≥ 6 to ≤ 17 Y); Day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="NA">No data as only adults to be enrolled to this group</measurement>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="NA">No data as only adults to be enrolled to this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills(≥ 6 to ≤ 17 Y); Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="NA">No data as only adults to be enrolled to this group</measurement>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="NA">No data as only adults to be enrolled to this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills(≥ 6 to ≤ 17 Y); Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not assessed at Day 29 for this group</measurement>
                    <measurement group_id="O2" value="NA">No data as only adults to be enrolled to this group</measurement>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="NA">No data as only adults to be enrolled to this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea ( ≥ 6 to ≤ 17 Y); Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="NA">No data as only adults to be enrolled to this group</measurement>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="NA">No data as only adults to be enrolled to this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea ( ≥ 6 to ≤ 17 Y); Day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="NA">No data as only adults to be enrolled to this group</measurement>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="NA">No data as only adults to be enrolled to this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea ( ≥ 6 to ≤ 17 Y); Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="NA">No data as only adults to be enrolled to this group</measurement>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="NA">No data as only adults to be enrolled to this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea ( ≥ 6 to ≤ 17 Y); Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not assessed at Day 29 for this group</measurement>
                    <measurement group_id="O2" value="NA">No data as only adults to be enrolled to this group</measurement>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="NA">No data as only adults to be enrolled to this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Generalized Myalgia (≥ 6 to ≤ 17 Y); Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="NA">No data as only adults to be enrolled to this group</measurement>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="NA">No data as only adults to be enrolled to this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Generalized Myalgia (≥ 6 to ≤ 17 Y); Day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="NA">No data as only adults to be enrolled to this group</measurement>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="NA">No data as only adults to be enrolled to this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Generalized Myalgia (≥ 6 to ≤ 17 Y); Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="NA">No data as only adults to be enrolled to this group</measurement>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="NA">No data as only adults to be enrolled to this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Generalized Myalgia (≥ 6 to ≤ 17 Y); Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not assessed at Day 29 for this group</measurement>
                    <measurement group_id="O2" value="NA">No data as only adults to be enrolled to this group</measurement>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="NA">No data as only adults to be enrolled to this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Generalized Arthralgia (≥ 6 to ≤ 17 Y); Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="NA">No data as only adults to be enrolled to this group</measurement>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="NA">No data as only adults to be enrolled to this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Generalized Arthralgia (≥ 6 to ≤ 17 Y); Day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="NA">No data as only adults to be enrolled to this group</measurement>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="NA">No data as only adults to be enrolled to this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Generalized Arthralgia (≥ 6 to ≤ 17 Y); Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="NA">No data as only adults to be enrolled to this group</measurement>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="NA">No data as only adults to be enrolled to this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Generalized Arthralgia (≥ 6 to ≤ 17 Y); Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not assessed at Day 29 for this group</measurement>
                    <measurement group_id="O2" value="NA">No data as only adults to be enrolled to this group</measurement>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="NA">No data as only adults to be enrolled to this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache (≥ 6 to ≤ 17 Y); Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="NA">No data as only adults to be enrolled to this group</measurement>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="NA">No data as only adults to be enrolled to this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache (≥ 6 to ≤ 17 Y); Day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="NA">No data as only adults to be enrolled to this group</measurement>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="NA">No data as only adults to be enrolled to this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache (≥ 6 to ≤ 17 Y); Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="NA">No data as only adults to be enrolled to this group</measurement>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="NA">No data as only adults to be enrolled to this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache (≥ 6 to ≤ 17 Y); Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not assessed at Day 29 for this group</measurement>
                    <measurement group_id="O2" value="NA">No data as only adults to be enrolled to this group</measurement>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="NA">No data as only adults to be enrolled to this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue (≥ 6 to ≤ 17 Y); Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="NA">No data as only adults to be enrolled to this group</measurement>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="NA">No data as only adults to be enrolled to this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue (≥ 6 to ≤ 17 Y); Day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="NA">No data as only adults to be enrolled to this group</measurement>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="NA">No data as only adults to be enrolled to this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue (≥ 6 to ≤ 17 Y); Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="NA">No data as only adults to be enrolled to this group</measurement>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="NA">No data as only adults to be enrolled to this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue (≥ 6 to ≤ 17 Y); Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not assessed at Day 29 for this group</measurement>
                    <measurement group_id="O2" value="NA">No data as only adults to be enrolled to this group</measurement>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="NA">No data as only adults to be enrolled to this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash (≥ 6 to ≤ 17 Y); Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="NA">No data as only adults to be enrolled to this group</measurement>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="NA">No data as only adults to be enrolled to this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash (≥ 6 to ≤ 17 Y); Day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="NA">No data as only adults to be enrolled to this group</measurement>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="NA">No data as only adults to be enrolled to this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash (≥ 6 to ≤ 17 Y); Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="NA">No data as only adults to be enrolled to this group</measurement>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="NA">No data as only adults to be enrolled to this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash (≥ 6 to ≤ 17 Y); Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not assessed at Day 29 for this group</measurement>
                    <measurement group_id="O2" value="NA">No data as only adults to be enrolled to this group</measurement>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="NA">No data as only adults to be enrolled to this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomitting (≥ 6 to ≤ 17 Y); Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="NA">No data as only adults to be enrolled to this group</measurement>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="NA">No data as only adults to be enrolled to this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomitting (≥ 6 to ≤ 17 Y); Day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="NA">No data as only adults to be enrolled to this group</measurement>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="NA">No data as only adults to be enrolled to this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomitting (≥ 6 to ≤ 17 Y); Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="NA">No data as only adults to be enrolled to this group</measurement>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="NA">No data as only adults to be enrolled to this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomitting (≥ 6 to ≤ 17 Y); Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not assessed at Day 29 for this group</measurement>
                    <measurement group_id="O2" value="NA">No data as only adults to be enrolled to this group</measurement>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="NA">No data as only adults to be enrolled to this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea (≥ 6 to ≤ 17 Y); Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="NA">No data as only adults to be enrolled to this group</measurement>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="NA">No data as only adults to be enrolled to this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea (≥ 6 to ≤ 17 Y); Day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="NA">No data as only adults to be enrolled to this group</measurement>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="NA">No data as only adults to be enrolled to this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea (≥ 6 to ≤ 17 Y); Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="NA">No data as only adults to be enrolled to this group</measurement>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="NA">No data as only adults to be enrolled to this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea (≥ 6 to ≤ 17 Y); Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not assessed at Day 29 for this group</measurement>
                    <measurement group_id="O2" value="NA">No data as only adults to be enrolled to this group</measurement>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="NA">No data as only adults to be enrolled to this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Loss Of Appetite (≥ 6 to ≤ 17 Y); Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="NA">No data as only adults to be enrolled to this group</measurement>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="NA">No data as only adults to be enrolled to this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Loss Of Appetite (≥ 6 to ≤ 17 Y); Day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="NA">No data as only adults to be enrolled to this group</measurement>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="NA">No data as only adults to be enrolled to this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Loss Of Appetite (≥ 6 to ≤ 17 Y); Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="NA">No data as only adults to be enrolled to this group</measurement>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="NA">No data as only adults to be enrolled to this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Loss Of Appetite (≥ 6 to ≤ 17 Y); Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not assessed at Day 29 for this group</measurement>
                    <measurement group_id="O2" value="NA">No data as only adults to be enrolled to this group</measurement>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="NA">No data as only adults to be enrolled to this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills (≥ 18 Y); Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills (≥ 18 Y); Day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills (≥ 18 Y); Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills (≥ 18 Y); Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not assessed at Day 29 for this group</measurement>
                    <measurement group_id="O2" value="NA">Not assessed at Day 29 for this group</measurement>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea,( ≥ 18 Y); Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea,( ≥ 18 Y); Day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea,( ≥ 18 Y); Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea,( ≥ 18 Y); Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not assessed at Day 29 for this group</measurement>
                    <measurement group_id="O2" value="NA">Not assessed at Day 29 for this group</measurement>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Generalized Myalgia (≥ 18 Y); Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="19"/>
                    <measurement group_id="O4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Generalized Myalgia (≥ 18 Y); Day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Generalized Myalgia (≥ 18 Y); Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Generalized Myalgia (≥ 18 Y); Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not assessed at Day 29 for this group</measurement>
                    <measurement group_id="O2" value="NA">Not assessed at Day 29 for this group</measurement>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Generalized Arthralgia (≥ 18 Y); Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Generalized Arthralgia (≥ 18 Y); Day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Generalized Arthralgia (≥ 18 Y); Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Generalized Arthralgia (≥ 18 Y); Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not assessed at Day 29 for this group</measurement>
                    <measurement group_id="O2" value="NA">Not assessed at Day 29 for this group</measurement>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache (≥ 18 Y); Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache (≥ 18 Y); Day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache (≥ 18 Y); Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache (≥ 18 Y); Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not assessed at Day 29 for this group</measurement>
                    <measurement group_id="O2" value="NA">Not assessed at Day 29 for this group</measurement>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue (≥ 18 Y); Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="19"/>
                    <measurement group_id="O4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue (≥ 18 Y); Day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue (≥ 18 Y); Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue (≥ 18 Y); Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not assessed at Day 29 for this group</measurement>
                    <measurement group_id="O2" value="NA">Not assessed at Day 29 for this group</measurement>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash (≥ 18 Y); Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash (≥ 18 Y); Day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash (≥ 18 Y); Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash (≥ 18 Y); Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not assessed at Day 29 for this group</measurement>
                    <measurement group_id="O2" value="NA">Not assessed at Day 29 for this group</measurement>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomitting (≥ 18 Y); Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomitting (≥ 18 Y); Day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomitting (≥ 18 Y); Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomitting (≥ 18 Y); Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not assessed at Day 29 for this group</measurement>
                    <measurement group_id="O2" value="NA">Not assessed at Day 29 for this group</measurement>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea (≥ 18 Y); Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea (≥ 18 Y); Day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea (≥ 18 Y); Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea (≥ 18 Y); Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not assessed at Day 29 for this group</measurement>
                    <measurement group_id="O2" value="NA">Not assessed at Day 29 for this group</measurement>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Loss Of Appetite (≥ 18 Y); Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Loss Of Appetite (≥ 18 Y); Day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Loss Of Appetite (≥ 18 Y); Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Loss Of Appetite (≥ 18 Y); Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not assessed at Day 29 for this group</measurement>
                    <measurement group_id="O2" value="NA">Not assessed at Day 29 for this group</measurement>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site tenderness (≥ 1 to ≤ 5 Y); Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="NA">No data as only adults to be enrolled to this group</measurement>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="NA">No data as only adults to be enrolled to this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site tenderness (≥ 1 to ≤ 5 Y); Day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="NA">No data as only adults to be enrolled to this group</measurement>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="NA">No data as only adults to be enrolled to this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site tenderness (≥ 1 to ≤ 5 Y); Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="NA">No data as only adults to be enrolled to this group</measurement>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="NA">No data as only adults to be enrolled to this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site tenderness (≥ 1 to ≤ 5 Y); Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not assessed at Day 29 for this group</measurement>
                    <measurement group_id="O2" value="NA">No data as only adults to be enrolled to this group</measurement>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="NA">No data as only adults to be enrolled to this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site pain (≥ 6 to ≤ 17 Y); Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="NA">No data as only adults to be enrolled to this group</measurement>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="NA">No data as only adults to be enrolled to this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site pain (≥ 6 to ≤ 17 Y); Day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="NA">No data as only adults to be enrolled to this group</measurement>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="NA">No data as only adults to be enrolled to this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site pain (≥ 6 to ≤ 17 Y); Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="NA">No data as only adults to be enrolled to this group</measurement>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="NA">No data as only adults to be enrolled to this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site pain (≥ 6 to ≤ 17 Y); Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not assessed at Day 29 for this group</measurement>
                    <measurement group_id="O2" value="NA">No data as only adults to be enrolled to this group</measurement>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="NA">No data as only adults to be enrolled to this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site pain (≥ 18 Y); Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site pain (≥ 18 Y); Day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site pain (≥ 18 Y); Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="21"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site pain (≥ 18 Y); Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not assessed at Day 29 for this group</measurement>
                    <measurement group_id="O2" value="NA">Not assessed at Day 29 for this group</measurement>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Unsolicited Adverse Events (AEs)</title>
        <description>Safety was assessed in terms of the Number of Subjects Reporting Unsolicited Adverse Events (AEs)</description>
        <time_frame>Day 1 to Day 366</time_frame>
        <population>Unsolicited Safety Set- All subjects in the Exposed Population who have post vaccination unsolicited adverse event records. The number of exposed set participants analyzed for safety is different from the Per Protocol Set (PPS) for immunogenicity.</population>
        <group_list>
          <group group_id="O1">
            <title>4-sites, 1-week WITHOUT HRIG</title>
            <description>12 doses of the PCEC rabies vaccine, administered ID (0.1mL for each injection) according to the “4-sites, 1-week” regimen</description>
          </group>
          <group group_id="O2">
            <title>4-sites, 1-week WITH HRIG</title>
            <description>12 doses of the PCEC rabies vaccine, administered ID (0.1mL for each injection) to adults only, according to the “4-sites, 1-week” regimen HRIG administered on day 1 (before the first dose of the vaccine) in a dose of 20 IU/kg body weight</description>
          </group>
          <group group_id="O3">
            <title>2-sites, TRC WITHOUT HRIG</title>
            <description>8 doses of the PCEC rabies vaccine, administered ID (0.1ml for each injection) according to the “2-sites, TRC”, updated Thai Red Cross regimen</description>
          </group>
          <group group_id="O4">
            <title>2-sites, TRC WITH HRIG</title>
            <description>8 doses of the PCEC rabies vaccine, administered ID (0.1ml for each injection) to adults only, according to the “2-sites, TRC”, updated Thai Red Cross regimen. HRIG administered on day 1 (before the first dose of the vaccine) in a dose of 20 IU/kg body weight intramuscularly</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Unsolicited Adverse Events (AEs)</title>
          <description>Safety was assessed in terms of the Number of Subjects Reporting Unsolicited Adverse Events (AEs)</description>
          <population>Unsolicited Safety Set- All subjects in the Exposed Population who have post vaccination unsolicited adverse event records. The number of exposed set participants analyzed for safety is different from the Per Protocol Set (PPS) for immunogenicity.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="356"/>
                <count group_id="O2" value="85"/>
                <count group_id="O3" value="353"/>
                <count group_id="O4" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>≥ 1 to ≤ 5 Y Any AEs;D1-366</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="NA">No data as only adults to be enrolled to this group</measurement>
                    <measurement group_id="O3" value="53"/>
                    <measurement group_id="O4" value="NA">No data as only adults to be enrolled to this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 1 to ≤ 5 Y SAE;D1-366</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="NA">No data as only adults to be enrolled to this group</measurement>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="NA">No data as only adults to be enrolled to this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 1 to ≤ 5 Y At least possibly related SAEs;D1-366</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="NA">No data as only adults to be enrolled to this group</measurement>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="NA">No data as only adults to be enrolled to this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 1 to ≤ 5 Y Deaths;D1-366</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="NA">No data as only adults to be enrolled to this group</measurement>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="NA">No data as only adults to be enrolled to this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥1 to ≤ 5 Y Withdrawal from study due to AE;D1-366</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="NA">No data as only adults to be enrolled to this group</measurement>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="NA">No data as only adults to be enrolled to this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 6 to ≤ 17 Y Any AEs;D1-366</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="NA">No data as only adults to be enrolled to this group</measurement>
                    <measurement group_id="O3" value="71"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 6 to ≤ 17 Y SAE;D1-366</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="NA">No data as only adults to be enrolled to this group</measurement>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="NA">No data as only adults to be enrolled to this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥6 to ≤ 17 Y At least possibly related SAEs;D1-366</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="NA">No data as only adults to be enrolled to this group</measurement>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="NA">No data as only adults to be enrolled to this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 6 to ≤ 17 Y Deaths;D1-366</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="NA">No data as only adults to be enrolled to this group</measurement>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="NA">No data as only adults to be enrolled to this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥6 to ≤17 Y Withdrawal from study due to AE;D1-366</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="NA">No data as only adults to be enrolled to this group</measurement>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="NA">No data as only adults to be enrolled to this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 18 Y Any AEs;D1-366</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="157"/>
                    <measurement group_id="O2" value="71"/>
                    <measurement group_id="O3" value="156"/>
                    <measurement group_id="O4" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 18 Y SAE;D1-366</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 18 Y At least possibly related SAEs;D1-366</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 18 Y Deaths;D1-366</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 18 Y Withdrawal from study due to AE;D1-366</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall population ≥ 1 Y Any AEs;D1-366</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="260"/>
                    <measurement group_id="O2" value="71"/>
                    <measurement group_id="O3" value="280"/>
                    <measurement group_id="O4" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall population ≥ 1 Y SAE;D1-366</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall ≥1Y Atleast possibly related SAEs;D1-366</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall population ≥ 1 Y Deaths;D1-366</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall population ≥1Y Withdrawal due to AE;D1-366</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Rabies Virus Neutralizing Antibody (RVNA) Concentration ≥0.5 IU/mL and Vaccine Group Differences in Adult Subjects, ≥ 18 Years of Age</title>
        <description>Immunogenicity was assessed in terms of the Geometric Mean Rabies Virus Neutralizing Antibody (RVNA) Concentration ≥0.5 IU/mL at Days 8, 15, 50,91, 181 and 366 in Adult Subjects, ≥ 18 Years of Age</description>
        <time_frame>At Days 8, 15, 50, 91, 181 and 366</time_frame>
        <population>Per Protocol Set (PPS): all subjects who correctly receive the vaccine doses, provided immunogenicity data at the relevant time points and were not excluded due to reasons defined prior to the analysis. This outcome measure is applicable only for 4-sites, 1-week with HRIG and 2-sites TRC with HRIG Groups.</population>
        <group_list>
          <group group_id="O1">
            <title>4-sites, 1-week WITH HRIG</title>
            <description>12 doses of the PCEC rabies vaccine, administered ID (0.1mL for each injection) to adults only, according to the “4-sites, 1-week” regimen HRIG administered on day 1 (before the first dose of the vaccine) in a dose of 20 IU/kg body weight</description>
          </group>
          <group group_id="O2">
            <title>2-sites TRC WITH HRIG</title>
            <description>8 doses of the PCEC rabies vaccine, administered ID (0.1ml for each injection) to adults only, according to the “2-sites, TRC”, updated Thai Red Cross regimen, with or without HRIG administered on day 1</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Rabies Virus Neutralizing Antibody (RVNA) Concentration ≥0.5 IU/mL and Vaccine Group Differences in Adult Subjects, ≥ 18 Years of Age</title>
          <description>Immunogenicity was assessed in terms of the Geometric Mean Rabies Virus Neutralizing Antibody (RVNA) Concentration ≥0.5 IU/mL at Days 8, 15, 50,91, 181 and 366 in Adult Subjects, ≥ 18 Years of Age</description>
          <population>Per Protocol Set (PPS): all subjects who correctly receive the vaccine doses, provided immunogenicity data at the relevant time points and were not excluded due to reasons defined prior to the analysis. This outcome measure is applicable only for 4-sites, 1-week with HRIG and 2-sites TRC with HRIG Groups.</population>
          <units>IU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (N= 66, 72)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" lower_limit="0.05" upper_limit="0.05"/>
                    <measurement group_id="O2" value="0.05" lower_limit="0.05" upper_limit="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8 (N= 66, 72)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.21" lower_limit="0.17" upper_limit="0.26"/>
                    <measurement group_id="O2" value="0.17" lower_limit="0.14" upper_limit="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15 (N= 65, 72)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13" lower_limit="11" upper_limit="15"/>
                    <measurement group_id="O2" value="8.37" lower_limit="6.96" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 50 (N= 65, 69)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.97" lower_limit="1.6" upper_limit="2.43"/>
                    <measurement group_id="O2" value="6.37" lower_limit="5.21" upper_limit="7.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 91 (N= 65, 72)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.01" lower_limit="0.81" upper_limit="1.27"/>
                    <measurement group_id="O2" value="2.25" lower_limit="1.81" upper_limit="2.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 181 (N= 65, 71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.88" lower_limit="0.67" upper_limit="1.14"/>
                    <measurement group_id="O2" value="1.05" lower_limit="0.81" upper_limit="1.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 366 (N= 65, 69)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.68" lower_limit="0.53" upper_limit="0.88"/>
                    <measurement group_id="O2" value="0.59" lower_limit="0.46" upper_limit="0.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects With Anti-RVNA Titer ≥0.5 IU/mL in Adult Subjects, ≥ 18 Years of Age</title>
        <description>Immunogenicity was assessed in terms of the number of subjects With Anti-RVNA concentration ≥0.5 IU/mL at Days 8, 15, 50, 91, 181 and 366 in Adult Subjects, ≥ 18 Years of Age</description>
        <time_frame>At Days 8, 15,50, 91, 181 and 366</time_frame>
        <population>Per Protocol Set (PPS): all subjects who correctly receive the vaccine doses, provided immunogenicity data at the relevant time points and were not excluded due to reasons defined prior to the analysis. This outcome measure is applicable only for 4-sites, 1-week with HRIG and 2-sites, TRC with HRIG Groups</population>
        <group_list>
          <group group_id="O1">
            <title>4-sites, 1-week WITH HRIG</title>
            <description>12 doses of the PCEC rabies vaccine, administered ID (0.1mL for each injection) to adults only, according to the “4-sites, 1-week” regimen HRIG administered on day 1 (before the first dose of the vaccine) in a dose of 20 IU/kg body weight</description>
          </group>
          <group group_id="O2">
            <title>2-sites, TRC WITH HRIG</title>
            <description>8 doses of the PCEC rabies vaccine, administered ID (0.1ml for each injection) to adults only, according to the “2-sites, TRC”, updated Thai Red Cross regimen, with or without HRIG administered on day 1</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects With Anti-RVNA Titer ≥0.5 IU/mL in Adult Subjects, ≥ 18 Years of Age</title>
          <description>Immunogenicity was assessed in terms of the number of subjects With Anti-RVNA concentration ≥0.5 IU/mL at Days 8, 15, 50, 91, 181 and 366 in Adult Subjects, ≥ 18 Years of Age</description>
          <population>Per Protocol Set (PPS): all subjects who correctly receive the vaccine doses, provided immunogenicity data at the relevant time points and were not excluded due to reasons defined prior to the analysis. This outcome measure is applicable only for 4-sites, 1-week with HRIG and 2-sites, TRC with HRIG Groups</population>
          <units>Percentages of Subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (N= 66, 72)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="5"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8 (N= 66, 72)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8" lower_limit="3" upper_limit="17"/>
                    <measurement group_id="O2" value="10" lower_limit="4" upper_limit="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15 (N= 65, 72)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="94" upper_limit="100"/>
                    <measurement group_id="O2" value="99" lower_limit="93" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 50 (N= 65, 69)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95" lower_limit="87" upper_limit="99"/>
                    <measurement group_id="O2" value="100" lower_limit="95" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 91 (N= 65, 72)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83" lower_limit="72" upper_limit="91"/>
                    <measurement group_id="O2" value="99" lower_limit="93" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 181 (N= 65, 71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77" lower_limit="65" upper_limit="86"/>
                    <measurement group_id="O2" value="85" lower_limit="74" upper_limit="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 366 (N= 65, 69)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66" lower_limit="53" upper_limit="77"/>
                    <measurement group_id="O2" value="70" lower_limit="57" upper_limit="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Day 1 to day 366 (Study Groups: A1- 4-sites, 1-week” (4-4-4-0-0) ID PEP regimen without HRIG, A2- 4-sites, 1-week” (4-4-4-0-0) ID PEP regimen with HRIG, B1- 2-sites TRC” (2-2-2-0-2) ID PEP regimen without HRIG, B2- 2-sites TRC” (2-2-2-0-2) ID PEP regimen with HRIG).</time_frame>
      <desc>Solicited local,systemic AEs &amp; associated medications will be recorded on diary cards for 3,4, 7 &amp; 7 days post vaccination on Visits 1,2,3 &amp; 5,respectively.Unsolicited AEs &amp; associated vaccinations will be collected in diary cards from D1-29 for Groups A1 &amp; A2 &amp; from D1-50 for Groups B1 &amp; B2.After D29/50, until D366 only SAEs &amp; AEs leading to withdrawal &amp; associated vaccinations will be recorded.Number of exposed set participants analyzed for safety is different from the PPS for immunogenicity.</desc>
      <group_list>
        <group group_id="E1">
          <title>4-sites, 1-week WITHOUT HRIG</title>
          <description>12 doses of the PCEC rabies vaccine, administered ID (0.1mL for each injection) according to the “4-sites, 1-week” regimen</description>
        </group>
        <group group_id="E2">
          <title>4-sites, 1-week WITH HRIG</title>
          <description>12 doses of the PCEC rabies vaccine, administered ID (0.1mL for each injection) to adults only, according to the “4-sites, 1-week” regimen HRIG administered on day 1 (before the first dose of the vaccine) in a dose of 20 IU/kg body weight</description>
        </group>
        <group group_id="E3">
          <title>2-sites, TRC WITHOUT HRIG</title>
          <description>8 doses of the PCEC rabies vaccine, administered ID (0.1ml for each injection) according to the “2-sites, TRC”, updated Thai Red Cross regimen.</description>
        </group>
        <group group_id="E4">
          <title>2-sites, TRC WITH HRIG</title>
          <description>8 doses of the PCEC rabies vaccine, administered ID (0.1ml for each injection) to adults only, according to the “2-sites, TRC”, updated Thai Red Cross regimen. HRIG administered on day 1 (before the first dose of the vaccine) in a dose of 20 IU/kg body weight intramuscularly</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (17.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="353"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina Unstable</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Irritable Bowel Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendiceal Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Appendicitis Perforated</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Dengue Fever</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>HIV Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Hand-Foot-And-Mouth Disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Pseudomonal Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Animal Bite</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="353"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Animal Scratch</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="353"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Joint Dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Road Traffic Accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Dysfunctional Uterine Bleeding</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (17.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="292" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="78" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="298" subjects_at_risk="353"/>
                <counts group_id="E4" subjects_affected="82" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="353"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="353"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="353"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>CHILLS</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="353"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="52" subjects_at_risk="353"/>
                <counts group_id="E4" subjects_affected="24" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>INJECTION SITE ERYTHEMA</sub_title>
                <counts group_id="E1" subjects_affected="195" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="59" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="168" subjects_at_risk="353"/>
                <counts group_id="E4" subjects_affected="56" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>INJECTION SITE INDURATION</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="62" subjects_at_risk="353"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>INJECTION SITE PAIN</sub_title>
                <counts group_id="E1" subjects_affected="77" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="89" subjects_at_risk="353"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>INJECTION SITE SWELLING</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="47" subjects_at_risk="353"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="353"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>VACCINATION SITE ERYTHEMA</sub_title>
                <counts group_id="E1" subjects_affected="82" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="79" subjects_at_risk="353"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>VACCINATION SITE INDURATION</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="353"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>VACCINATION SITE SWELLING</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="353"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="353"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="353"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DECREASED APPETITE</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="353"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="353"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>MYALGIA</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="41" subjects_at_risk="353"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="54" subjects_at_risk="353"/>
                <counts group_id="E4" subjects_affected="31" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>RASH</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="356"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="353"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis’ agreement with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publications of the pooled data (i.e., data from all sites) in the clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Posting Director</name_or_title>
      <organization>Novartis Vaccines</organization>
      <email>RegistryContactVaccinesUS@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

